Acadia Pharmaceuticals (ACAD) Finished Goods (2016 - 2026)

Acadia Pharmaceuticals' Finished Goods history runs 11 years deep, the most recent figure standing at $33.2 million for Q1 2026.

• In Q1 2026, Finished Goods rose 39.0% year-over-year to $33.2 million; the TTM figure through Mar 2026 stood at $33.2 million (up 39.0% YoY), while the FY2025 annual figure was $26.0 million, up 26.84% from the prior year.
• Finished Goods was $33.2 million for Q1 2026 at Acadia Pharmaceuticals, up from $26.0 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $33.2 million in Q1 2026 to a low of $1.6 million in Q1 2023.
• Historically, Finished Goods has averaged $12.7 million across 5 years, with a median of $7.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Finished Goods decreased 7.75% in 2023, then jumped 758.53% in 2024.
• A 5-year view of Finished Goods shows it stood at $1.9 million in 2022, then soared by 159.66% to $5.0 million in 2023, then jumped by 309.14% to $20.5 million in 2024, then grew by 26.84% to $26.0 million in 2025, then gained by 27.81% to $33.2 million in 2026.
• The last three Finished Goods figures came in at $33.2 million (Q1 2026), $26.0 million (Q4 2025), and $25.0 million (Q3 2025), per Business Quant data.